The Technical Analyst
Elanco Animal Health Inc [ELAN]
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Elanco Animal Health Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
24.93% $16.89
America/New_York / 8 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8 345.30 mill |
| EPS: | -2.50 |
| P/E: | -6.76 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 494.10 mill |
| Avg Daily Volume: | 4.08 mill |
| RATING 2024-05-08 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.76 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -6.76 | industry: PE 102.44 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-8.27 (-148.98%) $-25.16 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 16.46 - 17.33 ( +/- 2.58%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-03 | Modi Rajeev A. | Buy | 102 | Deferred Stock Units |
| 2024-05-03 | Simmons Jeffrey N | Buy | 205 | Deferred Stock Units |
| 2024-04-19 | Simmons Jeffrey N | Buy | 214 | Deferred Stock Units |
| 2024-04-19 | Modi Rajeev A. | Buy | 107 | Deferred Stock Units |
| 2024-04-05 | Simmons Jeffrey N | Buy | 178 | Deferred Stock Units |
| INSIDER POWER |
|---|
| 70.46 |
| Last 98 transactions |
| Buy: 1 815 404 | Sell: 309 971 |
Forecast:
16:00 - $16.89
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $16.89
Forecast 2: 16:00 - $16.89
Forecast 3: 16:00 - $16.89
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.89 (24.93% ) |
| Volume | 19.73 mill |
| Avg. Vol. | 4.08 mill |
| % of Avg. Vol | 483.12 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ELAN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Latest Press Releases
2024-05-08 06:28:00 - Press Release
Elanco Animal Health Reports First Quarter 2024 Results
First quarter 2024 financial results revenue of $1,205 million reported net income of $32 million, adjusted net income of $167 million adjusted ebitda of $294 million, or 24.4% of revenue reported eps of $0.06, adjusted eps of $0.34 net leverage ratio of 6.1x adjusted ebitda year over year growth rates are meaningfully impacted by a shift in customer purchasing related to the erp blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023 updating full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates: revenue of $4,460 to $4,515 million, constant currency growth improves to 2% to 3% reported net loss of $(3) to $(45) million; reported eps of $(0...
2024-04-17 08:00:00 - Press Release
Elanco Confirms Date And Conference Call For First Quarter 2024 Financial Results Announcement
Greenfield, ind. , april 17, 2024 /prnewswire/ -- elanco animal health incorporated (nyse: elan) will announce its first quarter 2024 financial results on wednesday, may 8, 2024.
2024-04-01 06:30:00 - Press Release
Elanco Appoints Two Animal Health Industry Executives, Kathy Turner And Craig Wallace, To Its Board Of Directors
New directors join the board's renamed finance, strategy and oversight committee reaches cooperation agreement with ancora greenfield, ind. , april 1, 2024 /prnewswire/ -- elanco animal health incorporated (nyse: elan) today announced that it has appointed two new independent directors, kathy turner and craig wallace, to its board of directors (the "board"), effective immediately, expanding the board to 14 members.
2024-03-04 08:33:00 - Press Release
Elanco Appoints Shiv O'neill As General Counsel And Corporate Secretary
Greenfield, ind. , march 4, 2024 /prnewswire/ -- elanco animal health (nyse: elan) announced today the appointment of shiv o'neill as the company's executive vice president, general counsel and corporate secretary.
2024-02-29 13:08:00 - Press Release
Elanco Animal Health Is Executing On Plan To Deliver For Shareholders
Ancora nominates director candidates despite elanco's meaningful operational progress and good faith engagement with the investor greenfield, ind. , feb. 29, 2024 /prnewswire/ -- elanco animal health incorporated (nyse: elan) today issued the following statement in response to the submission of four nominees to the company's board of directors by ancora holdings group, llc ("ancora"): the execution of elanco's innovation, portfolio and productivity strategy, led by ceo jeff simmons, is working.
Latest News
2024-05-08 18:46:56 - Schwab Network
Elanco Animal Health (ELAN) CEO on Earnings
Elanco Animal Health (ELAN) CEO Jeffrey Simmons joins Oliver Renick to discuss ELAN's 1Q earnings. He talks about how ELAN's shares hit a 52-week high.
2024-05-08 10:36:40 - Zacks Investment Research
Elanco Animal Health (ELAN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2024-05-06 10:22:40 - Zacks Investment Research
Countdown to Elanco Animal Health (ELAN) Q1 Earnings: Wall Street Forecasts for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Elanco Animal Health (ELAN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
2024-03-31 23:49:57 - Reuters
Activist investor Ancora secures two Elanco board seats, Bloomberg News reports
Investment firm Ancora Holdings has reached an agreement with Elanco Animal Health to add two of its director candidates to the company's board, Bloomberg News reported late on Sunday, citing people with knowledge of the matter.
2024-03-11 12:14:44 - Schwab Network
Elanco Animal Health (ELAN) CEO on Pet Disease Prevention & Health Products
Elanco Animal Health (ELAN) offers pet disease prevention and nutritional health products. CEO Jeffrey Simmons joins Oliver Renick to give an overview of the company.
2024-02-26 10:31:17 - Zacks Investment Research
Here's What Key Metrics Tell Us About Elanco Animal Health Incorporated (ELAN) Q4 Earnings
The headline numbers for Elanco Animal Health Incorporated (ELAN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2024-02-21 10:20:44 - Zacks Investment Research
Elanco Animal Health Incorporated (ELAN) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Elanco Animal Health Incorporated (ELAN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
2024-02-19 11:05:28 - Zacks Investment Research
Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-05 08:24:56 - Proactive Investors
Elanco Animal Health sells aqua business to Merck for $1.3 billion
Elanco Animal Health Inc has announced the sale of its aqua business to Merck Animal Health for US$1.3 billion in a bid to refocus on other markets. This will enable Elanco to accelerate debt paydown by US$1.05 billion to US$1.1 billion, the company said on Monday, with the proceeds representing over seven times the estimated 2023 revenue of the hot and cold water species product firm.
2024-02-05 06:43:00 - Market Watch
Elanco Animal Health agrees to sell aqua business to Merck for $1.3 billion in cash
Elanco Animal Health Inc. ELAN, -0.41% said Monday it has agreed to sell its aqua business to Merck Animal Health MRK, +0.02% for $1.3 billion in cash. Greenfield, Ind.